RU2016119132A - WAYS OF TREATMENT OF PATHOLOGICAL CONDITIONS OF THE EYE BY USING AN IMPLANT WITH LONG-TERM DELIVERY OF MEDICINE - Google Patents

WAYS OF TREATMENT OF PATHOLOGICAL CONDITIONS OF THE EYE BY USING AN IMPLANT WITH LONG-TERM DELIVERY OF MEDICINE Download PDF

Info

Publication number
RU2016119132A
RU2016119132A RU2016119132A RU2016119132A RU2016119132A RU 2016119132 A RU2016119132 A RU 2016119132A RU 2016119132 A RU2016119132 A RU 2016119132A RU 2016119132 A RU2016119132 A RU 2016119132A RU 2016119132 A RU2016119132 A RU 2016119132A
Authority
RU
Russia
Prior art keywords
biodegradable implant
implant
treatment
person
biodegradable
Prior art date
Application number
RU2016119132A
Other languages
Russian (ru)
Other versions
RU2690841C1 (en
Inventor
Джейн-Гуо ШИА
Рауль БАГАТ
Венди М. БЛАНДА
Тьерри НИВАГЖИОЛИ
Линь ПЭН
Дэвид ЧОУ
Дэвид А. ВЕБЕР
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016119132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2016119132A publication Critical patent/RU2016119132A/en
Application granted granted Critical
Publication of RU2690841C1 publication Critical patent/RU2690841C1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Claims (9)

1. Способ лечения диабетического макулярного отека (ДМО), включающий инъецирование биоразлагаемого имплантата в стекловидное тело человека с частотой от одного раза в примерно шесть месяцев до одного раза в примерно девять месяцев, причем биоразлагаемый имплантат содержит сплошной дважды экструдированный стержень, содержащий дексаметазон, гомогенно диспергированный в биодеградируемой полимерной матрице; при этом1. A method for the treatment of diabetic macular edema (DME), comprising injecting a biodegradable implant into the vitreous body of a person with a frequency of from once every six months to once every nine months, wherein the biodegradable implant contains a solid, twice extruded rod containing dexamethasone homogeneously dispersed in a biodegradable polymer matrix; wherein биодеградируемая полимерная матрица состоит из смеси поли(D,L-лактида-со-гликолида) (ПМГК), имеющего гидрофильные концевые группы, и поли(D,L-лактида-со-гликолида) (ПМГК), имеющего гидрофобные концевые группы; аa biodegradable polymer matrix consists of a mixture of poly (D, L-lactide-co-glycolide) (PMHC) having hydrophilic end groups and a poly (D, L-lactide-co-glycolide) (PMHC) having hydrophobic end groups; but биоразлагаемый имплантат имеет размер, подходящий для имплантации в стекловидное тело человека; и способ является терапевтически эффективным для лечения ДМО.biodegradable implant has a size suitable for implantation in the vitreous body of a person; and the method is therapeutically effective for the treatment of DMO. 2. Способ по п. 1, отличающийся тем, что человек невосприимчив к анти-VEGF-лечению ДМО.2. The method according to p. 1, characterized in that the person is immune to anti-VEGF treatment of DMO. 3. Способ по п. 1 или 2, отличающийся тем, что дексаметазон присутствует в биоразлагаемом имплантате в количестве 60% по массе в пересчете на общую массу биоразлагаемого имплантата.3. The method according to p. 1 or 2, characterized in that dexamethasone is present in the biodegradable implant in an amount of 60% by weight, based on the total weight of the biodegradable implant. 4. Способ по п. 1 или 2, отличающийся тем, что ПМГК, содержащая гидрофобные концевые группы, присутствует в биоразлагаемом имплантате в количестве 10% по массе в пересчете на общую массу биоразлагаемого имплантата.4. The method according to p. 1 or 2, characterized in that the PMHC containing hydrophobic end groups is present in the biodegradable implant in an amount of 10% by weight, based on the total weight of the biodegradable implant. 5. Способ по п. 1 или 2, отличающийся тем, что ПМГК, содержащая гидрофильные концевые группы, присутствует в биоразлагаемом имплантате в количестве 30% по массе в пересчете на общую массу биоразлагаемого имплантата.5. The method according to p. 1 or 2, characterized in that the PMHC containing hydrophilic end groups is present in the biodegradable implant in an amount of 30% by weight, based on the total weight of the biodegradable implant. 6. Способ по п. 1 или 2, отличающийся тем, что человек имеет псевдофакичную линзу.6. The method according to p. 1 or 2, characterized in that the person has a pseudophakic lens. 7. Способ по п. 1 или 2, отличающийся тем, что человек имеет факичную линзу.7. The method according to p. 1 or 2, characterized in that the person has a phakic lens.
RU2016119132A 2013-11-15 2014-11-14 Methods for treating pathology of eye by means of implant with durable delivery of drug subjects RU2690841C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Publications (2)

Publication Number Publication Date
RU2016119132A true RU2016119132A (en) 2017-12-20
RU2690841C1 RU2690841C1 (en) 2019-06-06

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016119132A RU2690841C1 (en) 2013-11-15 2014-11-14 Methods for treating pathology of eye by means of implant with durable delivery of drug subjects

Country Status (24)

Country Link
US (1) US20150140062A1 (en)
EP (2) EP3714875A1 (en)
JP (2) JP6675307B2 (en)
KR (3) KR20220082934A (en)
CN (1) CN105764517A (en)
AU (3) AU2014348369B2 (en)
CA (1) CA2929689A1 (en)
CL (1) CL2016001167A1 (en)
CY (1) CY1123344T1 (en)
DK (1) DK3068403T3 (en)
ES (1) ES2819215T3 (en)
HU (1) HUE050913T2 (en)
IL (2) IL245548A0 (en)
MX (2) MX2016006334A (en)
MY (1) MY176039A (en)
NZ (1) NZ719953A (en)
PH (1) PH12016500869B1 (en)
PL (1) PL3068403T3 (en)
PT (1) PT3068403T (en)
RU (1) RU2690841C1 (en)
SG (1) SG10201809363SA (en)
SI (1) SI3068403T1 (en)
UA (1) UA122117C2 (en)
WO (1) WO2015073895A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016297187A1 (en) * 2015-07-23 2018-02-15 Aerie Pharmaceuticals, Inc. Intravitreal drug delivery systems for the treatment of ocular conditions
WO2019226516A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068A (en) 2018-05-24 2020-11-24 塞拉尼斯伊娃高性能聚合物公司 Implantable devices for sustained release of macromolecular drug compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE306951T1 (en) 2000-11-29 2005-11-15 Allergan Inc PREVENTING TRANSPLANT REJECTION IN THE EYE
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
EP2673049A4 (en) * 2011-02-11 2015-04-08 Psivida Inc Methods of treating macular edema using antiedema therapeutics

Also Published As

Publication number Publication date
KR20160085847A (en) 2016-07-18
IL245548A0 (en) 2016-06-30
CY1123344T1 (en) 2021-12-31
RU2690841C1 (en) 2019-06-06
ES2819215T3 (en) 2021-04-15
JP2016538292A (en) 2016-12-08
AU2014348369A1 (en) 2016-06-09
SI3068403T1 (en) 2020-11-30
AU2022204607A1 (en) 2022-07-21
EP3714875A1 (en) 2020-09-30
WO2015073895A1 (en) 2015-05-21
JP2020055862A (en) 2020-04-09
KR102475746B1 (en) 2022-12-08
EP3068403A1 (en) 2016-09-21
CN105764517A (en) 2016-07-13
MX2016006334A (en) 2016-09-06
KR20220082934A (en) 2022-06-17
AU2020204362A1 (en) 2020-07-23
PL3068403T3 (en) 2021-01-11
SG10201809363SA (en) 2018-11-29
HUE050913T2 (en) 2021-01-28
PH12016500869A1 (en) 2016-07-04
EP3068403B1 (en) 2020-06-17
JP6675307B2 (en) 2020-04-01
JP7022735B2 (en) 2022-02-18
KR20240058976A (en) 2024-05-07
CL2016001167A1 (en) 2017-01-06
PT3068403T (en) 2020-09-18
DK3068403T3 (en) 2020-09-07
US20150140062A1 (en) 2015-05-21
IL290837A (en) 2022-04-01
NZ719953A (en) 2022-01-28
MY176039A (en) 2020-07-22
CA2929689A1 (en) 2015-05-21
AU2014348369B2 (en) 2020-04-02
UA122117C2 (en) 2020-09-25
MX2022002306A (en) 2022-03-25
PH12016500869B1 (en) 2016-07-04

Similar Documents

Publication Publication Date Title
RU2015134774A (en) IMPLANT FOR PROLONGED DELIVERY OF MEDICINES
MX2022006107A (en) Methods and compositions for dosing in adoptive cell therapy.
WO2016042163A3 (en) Ophthalmic drug compositions
EA201791337A1 (en) COMPOSITIONS OF SUITINIBA AND METHODS OF THEIR APPLICATION IN THE TREATMENT OF EYE DISTURBANCES
BR112015016867A2 (en) BIOANALOGICAL INTRAOCULAR LENS AND ITS IMPLANT
RU2011106329A (en) EYE DEVICE WITH POSSIBILITY OF DELIVERY OF THE THERAPEUTIC MEANS AND METHOD OF PRODUCING SUCH
MY178327A (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
RU2016119132A (en) WAYS OF TREATMENT OF PATHOLOGICAL CONDITIONS OF THE EYE BY USING AN IMPLANT WITH LONG-TERM DELIVERY OF MEDICINE
EA201791555A2 (en) METHOD OF MAKING PRODUCT CONTAINING GLATIRAMER ACETATE
BR112017024509A2 (en) treatment of cns disease with encapsulated inducible choroid plexus cells
HRP20220066T1 (en) Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
CY1123583T1 (en) AN IMMUNE COMPOSITION FOR USE IN THERAPY
RU2016136333A (en) PHARMACOLOGICAL OPHTHALMOLOGICAL COMPOSITION USED IN CORRECTION OF PRESBIOPIA AND ITS INTRODUCTION
JP2016538292A5 (en)
RU2018114634A (en) INTRODUCTION MODE COMBINATIONS OF ANTIBODY TO CD20 AND ANTIBODIES TO BLYS
EA202090966A1 (en) MONOCLONAL ANTI-TrkB ANTIBODIES AND METHODS OF THEIR APPLICATION
CO7461128A2 (en) Insulinotropic peptide derivative with modified n-terminal loading
RU2015149084A (en) Treatment and prophylactic material for dentistry
TH1601002766A (en) Methods for treating eye ailments with gradual drug delivery implants
Sosnovsky et al. ANALYSIS OF LONG-TERM COMPLICATIONS AFTER FORMING SUPPORT-MOTOR EYEBALL STUMP BY AN POLYTETRAFLUOROETHYLENE IMPLANT IN BACK EVISCERATION
RU2013153993A (en) METHOD FOR CORRECTION OF THE THYROID STATUS OF BREEDING RABBIT RABBITS IN THE ENDEMIC ZONES BY THE COMBINED USE OF IODINE AND SELENIUM
RU2014120624A (en) METHOD FOR TREATING A STROKE
Moisseiev Cataract progression and elevated intraocular pressure following intravitreal implantation: 11 case reports
EA201500761A1 (en) GRANULATED AGRICULTURAL HYDROGEL, ACCUMULATING AND RELEASING MOISTURE AND NUTRITIONAL SUBSTANCES, AND ITS MANUFACTURE AND APPLICATION
Ishkulova Pracice of surgical treatment of uveal cataract in children